The European Organisation for the Research and Treatment of Cancer (EORTC) supports the European Commissions initiative to simplify the EU rules for medical devices and to strengthen the competitiveness of the European medical device sector.
EOR
EORTC
NGO · Belgium · EU Transparency Register 70539554035-46
6
positions filed
in the 665 files tracked
4
legislative files
of 665 tracked
3
with a full position paper
attached to a submission
Counts here are a floor, never a total: they cover the 665 consultation files tracked so far (57,774 submissions, mostly 2021–26), so an organization's real filing history is larger, not smaller.
Who they are
Among the 1106 non-governmental organisations on this site, they rank #297 by legislative files engaged, a count of participation, not a measure of influence.
0.4
declared lobbying FTE
self-declared
–
declared costs / yr (floor)
0
EP accreditations
as declared to the register
2010
in the register since
Declares membership of
- American Association for Cancer Research
- American Society for Therapeutic Radiology and Oncology
- European Alliance for Personnalised Medicine
- European Association for NeuroOncology
- European Association of Urology →
- European Association of Urology →
- European Cancer Organisation →
- European Forum for Good Clinical Practice
- European Oncology Nursing Society
- European School of Oncology
- European Society for Medical Oncology
- European Society for Therapeutic Radiology and Oncology
- and 7 more
Self-declared to the EU Transparency Register (snapshot 14 Oct 2026).
- Register category
- Non-governmental organisations
- Registered as
- European Organisation for Research and Treatment of Cancer (EORTC)
- Head office
- Brussels, Belgium
Self-declared to the EU Transparency Register (snapshot 14 Oct 2026); cost bands are floors, not audited totals. Reused under Commission Decision 2011/833/EU.
Track EORTC in PolicySpeak: request access →
Work at EORTC? so we know who speaks for it.
Their record over time
EORTC filed 6 positions between 26 Jan 2021 and 2 Apr 2026, across 4 of the 665 legislative files tracked here, attaching a full position paper 3 times.
2021 · 2 filed2023 · 2 filed2025 · 1 filed2026 · 1 filed
What they argued
The European Organisation for Research and Treatment of Cancer (EORTC), with a mission to design, coordinate, and conduct multidisciplinary clinical and translational trials to improve the standard of cancer treatment for patients, welcomes the proposal to review the EU general pharmaceutical legislation. Many drugs enter the market without evidence of their true clinical benefit for patients.
The EORTC believes the revision of the general pharmaceutical legislation provides with an opportunity to introduce the concept of treatment optimisation into the legislation. What is treatment optimisation? Many drugs enter the market without evidence of their true clinical benefit for patients.
EORTC would like to stress several aspects that would deserve specific actions: Access to medicines is definitively a key aspect. The affordability of medicines has implications for both public and household finances. EORTC fully endorses the Commission statement that minimising waste and optimising the value of spending on medicines are also critical to achieving efficient and sustainable health systems.
The European Organisation for Research and Treatment of Cancer (EORTC) welcomes the Biotech Act as an initiative to support clinical research by improving the European legal framework. The Acts preamble explicitly outlines a commitment to supporting clinical trial sponsors, and particularly non-commercial sponsors that conduct the majority of minimal- and low-intervention clinical trials in the Union.
Generally speaking, creating an EU environment where data are available, accessible and interoperable can only be welcome. Data are complex and need to be informative on the disease, the host and their respective evolution overtime. Data are not static must should be seen as dynamic set of varying inter-dependent information.
Looking for an argument rather than an organization? Search every submission for a phrase and see everyone who used it.
Put EORTC next to another organization. Same files, same register facts, side by side. Compare →
Turns up on the same files
Organizations that also filed on at least two of the same consultations. A shared interest in the same dossiers, not evidence of coordination, and we do not suggest any.
Showing 5 of 135.
Is this your organization?
Everything on this page comes from EORTC’s own submissions to the European Commission. We have added nothing and interpreted nothing. If something is wrong or out of date, email info@policyspeak.com and we will correct it. If you are an individual named in a record, our privacy policy sets out your rights to correction, objection and removal.
Quotes are verbatim from submissions published by the European Commission, trimmed to their opening passage and never summarized by a model. Organizations only, never individuals. Reused under Commission Decision 2011/833/EU; the European Commission is not liable for this reuse.